Complain about a product or service

Side Effects Drive Women from Breast Cancer Drug

Study finds more than 10% stopped taking drugs because of pain

September 6, 2007

Breast Cancer • Recommended Changes to Breast Cancer Screenings Cause Controversy • Optical Biopsy Provides Surgery-Free Diagnosis • Breast Cancer Lawsuit Alleged Needless Suffering, Death • New Chemo Cocktail Blocks Breast Cancer 'Like A Fence' • Physically Fit Women Less Likely To Die Of Breast Cancer • No Link Found Between Caffeine and Breast Cancer Risk • Older Women at Greater Risk of Breast Cancer • Companies Agree To Cut Cancer-Causing Chemicals In Potato Chips • What Women -- and Men -- Should Know about Breast Cancer • Daily Aspirin May Reduce Risk of Breast Cancer • FDA Approves New Genetic Test for Breast Cancer • Gene Mutation Spreads Breast Cancer • Research Finds Green Tea Helpful Against Breast Cancer • Marijuana Compound May Fight Breast Cancer • Mayo Clinic Sees New Hope In Breast Cancer Drug • FDA Approves Evista For Reducing Breast Cancer Risk • Side Effects Drive Women from Breast Cancer Drug • Hypnosis Reduces Pain and Costs in Breast Cancer Surgery • Grapefruit Linked to Breast Cancer • Study Finds No Link Between Abortion, Miscarriage and Breast Cancer • Falling Breast Cancer Rates Linked to Declining Use of Hormone Replacement Therapy • Hispanic Women Three Times More Likely to Develop Advanced Breast Cancer • MRI Screening of Opposite Breast Necessary for Women with Breast Cancer • FDA Approves Tykerb for Advanced Breast Cancer Patients • FDA Clears New Breast Cancer Test • Needle Biopsy May Not Be Enough to Rule Out Breast Cancer in Some Cases • Red Meat May Increase Breast Cancer Risk • Breast Cancer Survivors Skipping Mammograms, Study Finds • Breast Implant Complications Frequent, Study Finds • Tests Show Drug Fights Aggressive Breast Cancer • California Sues to Require Cancer Warnings on Potato Chips and French Fries • Study Ties Fries To Breast Cancer Risk • Low-Fat Diet May Reduce Risk of Recurrent Breast Cancer • Study Suggests Pain Reliever, Breast Cancer Link • Trials Show Herceptin Aids Breast Cancer Recovery • That Pink Ribbon Can Be Misleading, Consumer Group Warns • Survival Better When Breast Cancer Detected Through Mammography

More than 10 percent of women with breast cancer stopped taking a commonly prescribed drug because of joint and muscle pain, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

The women in the study were taking aromatase inhibitors, a type of drug designed to block the production of estrogen, which fuels some breast cancers.

The treatment is generally given after surgery, chemotherapy or radiation therapy to prevent the cancer from returning. It’s typically prescribed as one pill each day for five years. Use of these drugs has increased because they have been shown to be more effective than tamoxifen, the previous standard of care.

“We know 25 percent to 30 percent of women taking aromatase inhibitors have aches and pains. What was surprising here was the number of people who actually discontinued the drugs because of the side effects," said N. Lynn Henry, M.D., Ph.D., lecturer in internal medicine at the U-M Medical School.

"Up to 15 percent of patients in previously reported studies stopped taking aromatase inhibitors for a variety of reasons, but in our study, we had 13 percent drop out just because of musculoskeletal problems,” Henry said.

The study looked at the first 100 women enrolled in a trial to study how genetics play a role in the way individuals metabolize drugs and experience side effects. The women in this analysis were all post-menopausal following treatment for hormone-responsive breast cancer. They were assigned to take one of two aromatase inhibitors, exemestane or letrozole, and were followed for at least six months.

Study participants completed questionnaires about their health and side effects. If their reported joint and muscle concerns scored above a certain threshold on these questionnaires, the women were referred to a rheumatologist.

Referrals were based on worsened pain or a change in function from the start of the study that resulted in more difficulty performing tasks such as rising from a chair, climbing out of a car or opening a jar.

In women who developed symptoms while taking the medication, the symptoms typically came on soon after starting treatment, at a median just under two months. The specific symptoms varied among the study participants, including tendonitis in the shoulder or wrist, inflammation in the knees or arthritis-type symptoms in the hands or hips. Some women reported joint pain while others had muscle pain.

The researchers are looking at interventions to determine how to manage the musculoskeletal side effects of these drugs. Symptoms almost always improve after stopping the drug.

Researchers are trying to determine if switching to a different aromatase inhibitor will prevent the side effects in women who are affected, and they’re testing interventions to manage the side effects. Another option is to switch from an aromatase inhibitor to tamoxifen, which also blocks estrogen but which is not known to cause as much joint and muscle pain.

Large randomized studies have shown aromatase inhibitors work better than tamoxifen in post-menopausal women to prevent breast cancer from recurring. But, Henry points out, given the risks and side effects an individual woman might face, tamoxifen might be the better choice for some women.

“Tamoxifen has been around 20-30 years and has a long track record. We know about its benefits and its risks. Aromatase inhibitors are new, and we don’t have as much experience with them. We have to see in the long term which one ends up being better,” Henry says.

The goal of the larger study, which is led by the Consortium on Breast Cancer Pharmacogenomics, is to determine if breast cancer treatment can be personalized based on an individual woman’s genetic make-up. At this point, the sample size is not large enough to determine any genetic markers.

Eventually, the researchers hope to enroll 500 women in the study. Finding a marker that predisposes a woman to more severe side effects could help doctors make personalized treatment decisions.

Report Your Experience
If you've had a bad experience -- or a good one -- with a consumer product or service, we'd like to hear about it. All complaints are reviewed by class action attorneys and are considered for publication on our site. Knowledge is power! Help spread the word. File your consumer report now.

Share		Follow us on Twitter.